<DOC>
	<DOC>NCT01601652</DOC>
	<brief_summary>The study will evaluate the safety and efficacy of an intravenous fish oil emulsion (omegaven) in infants with parenteral nutrition associated cholestasis.</brief_summary>
	<brief_title>Compassionate Use of an Intravenous Fish Oil Emulsion in Infants With Cholestasis</brief_title>
	<detailed_description />
	<mesh_term>Cholestasis</mesh_term>
	<criteria>Cholestasis defined as either serum bilirubin &gt; 2mg/dL (two measurements at least 8d apart) that has not responded to 4 weeks of intralipid being reduced to 1 g/kg/d and trace minerals being limited to twice weekly, OR serum bilirubin &gt; 6 mg/dL (single measurement) and rising, in the absence of proven or suspected sepsis Age &gt; 1y at time that omegaven is started Not expected to survive at least 30 days Fish allergy in a first degree relative Hemodynamic instability Coagulopathy Not likely to require PN for &gt; 30d Not expected to survive &gt; 30d</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>1 Year</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>cholestasis</keyword>
	<keyword>PNAC</keyword>
	<keyword>Parenteral Nutrition Associated Cholestasis</keyword>
	<keyword>PNALD</keyword>
	<keyword>Parenteral Nutrition Associated Liver Disease</keyword>
</DOC>